Traders assign an 82% implied probability to no Encore Medical IPO before June 2026 because the company’s planned May 2026 listing window on NYSE American has elapsed without pricing or trading, reflecting persistent delays in its $15 million S-1 offering. Encore Medical, a developer of transcatheter septal occlusion devices, filed its registration statement in September 2025 and set terms at $5 per share to fund ongoing FDA clinical trials for stroke and migraine indications. Recent market volatility in small-cap healthcare IPOs, coupled with the firm’s pre-revenue status and heavy reliance on clinical milestones, has likely prompted underwriters to postpone amid uncertain investor demand. This leaves the path to a 45–55 million closing market cap contingent on a swift re-filing or accelerated trial data release in the coming weeks.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트2026년 6월 이전에 상장 없음 82%
45M–50M 6%
5,000만–5,500만 4.0%
5,500만+ 4.0%
$24,088 거래량
$24,088 거래량
2026.04.22
$45M 미만
2%
45M–50M
6%
5,000만–5,500만
4%
5,500만+
4%
2026년 6월 이전에 상장 없음
82%
2026년 6월 이전에 상장 없음 82%
45M–50M 6%
5,000만–5,500만 4.0%
5,500만+ 4.0%
$24,088 거래량
$24,088 거래량
2026.04.22
$45M 미만
$7,323 거래량
2%
45M–50M
$2,625 거래량
6%
5,000만–5,500만
$1,823 거래량
4%
5,500만+
$3,121 거래량
4%
2026년 6월 이전에 상장 없음
$9,195 거래량
82%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Traders assign an 82% implied probability to no Encore Medical IPO before June 2026 because the company’s planned May 2026 listing window on NYSE American has elapsed without pricing or trading, reflecting persistent delays in its $15 million S-1 offering. Encore Medical, a developer of transcatheter septal occlusion devices, filed its registration statement in September 2025 and set terms at $5 per share to fund ongoing FDA clinical trials for stroke and migraine indications. Recent market volatility in small-cap healthcare IPOs, coupled with the firm’s pre-revenue status and heavy reliance on clinical milestones, has likely prompted underwriters to postpone amid uncertain investor demand. This leaves the path to a 45–55 million closing market cap contingent on a swift re-filing or accelerated trial data release in the coming weeks.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
마켓 개설일: Apr 3, 2026, 7:59 PM ET
거래량
$24,088종료일
2026.04.22마켓 개설일
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Traders assign an 82% implied probability to no Encore Medical IPO before June 2026 because the company’s planned May 2026 listing window on NYSE American has elapsed without pricing or trading, reflecting persistent delays in its $15 million S-1 offering. Encore Medical, a developer of transcatheter septal occlusion devices, filed its registration statement in September 2025 and set terms at $5 per share to fund ongoing FDA clinical trials for stroke and migraine indications. Recent market volatility in small-cap healthcare IPOs, coupled with the firm’s pre-revenue status and heavy reliance on clinical milestones, has likely prompted underwriters to postpone amid uncertain investor demand. This leaves the path to a 45–55 million closing market cap contingent on a swift re-filing or accelerated trial data release in the coming weeks.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
거래량
$24,088종료일
2026.04.22마켓 개설일
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Traders assign an 82% implied probability to no Encore Medical IPO before June 2026 because the company’s planned May 2026 listing window on NYSE American has elapsed without pricing or trading, reflecting persistent delays in its $15 million S-1 offering. Encore Medical, a developer of transcatheter septal occlusion devices, filed its registration statement in September 2025 and set terms at $5 per share to fund ongoing FDA clinical trials for stroke and migraine indications. Recent market volatility in small-cap healthcare IPOs, coupled with the firm’s pre-revenue status and heavy reliance on clinical milestones, has likely prompted underwriters to postpone amid uncertain investor demand. This leaves the path to a 45–55 million closing market cap contingent on a swift re-filing or accelerated trial data release in the coming weeks.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트
외부 링크에 주의하세요.
외부 링크에 주의하세요.
자주 묻는 질문